Enleofen Bio Pte Ltd

What Enleofen Bio Pte Ltd does

Enleofen Bio Pte Ltd is a Singapore-based biotechnology company founded in April 2017 as a spin-out from the National Heart Centre Singapore (NHCS) at SingHealth and Duke-NUS Medical School. The company is developing first-in-class antibody therapeutics that target the interleukin-11 (IL-11) cytokine pathway, which its founders Stuart Cook and Sebastian Schäfer identified as a master driver of fibrosis and tissue inflammation across multiple organs including the liver, lung, kidney, heart, retina, bowel, and skin. Its lead clinical development candidate, ENx108A, is a human monoclonal antibody that has demonstrated the ability to prevent, arrest, and reverse fibrosis and restore organ function in preclinical models across fibro-inflammatory indications such as non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), cardiovascular fibrosis, and chronic kidney disease.

The company's underlying technology consists of an extensive anti-IL-11 antibody platform with a comprehensive patent portfolio, originally licensed from the SingHealth Duke-NUS Academic Medical Centre and expanded internally. Enleofen does not sell products directly; instead, it operates a partnership/licensing business model in which it develops antibody candidates through preclinical and clinical stages, then licenses them to large pharmaceutical companies for clinical, regulatory, and commercial development. This model is exemplified by the January 2020 agreement with Boehringer Ingelheim, under which Enleofen granted worldwide exclusive rights to its preclinical IL-11 platform and is eligible for earn-out payments in excess of one billion USD per product in upfront and success-based milestones. Manufacturing support is provided by Abzena under a 2017 agreement, and Evercore Asia acted as exclusive financial adviser on the Boehringer Ingelheim transaction.

Enleofen serves large pharmaceutical companies seeking novel, first-in-class therapeutic platforms for fibrotic diseases, and ultimately targets patients suffering from fibro-inflammatory conditions for which no satisfactory treatment options currently exist. The company is privately held, headquartered at SBF Centre in Singapore's central business district, operates with a lean team of 1-10 employees, and has been recognized with Singapore's President's Technology Award (2018) for breakthrough IL-11 research. Strategic momentum is concentrated around milestone realization from the Boehringer Ingelheim partnership and ongoing platform development with academic founders.

Name

Enleofen Bio Pte Ltd

Legal name

Enleofen Bio Pte Ltd

Website

https://enleofen.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Enleofen Bio Pte Ltd is a Singapore-based biotechnology company developing first-in-class monoclonal antibody therapeutics that target the interleukin-11 (IL-11) pathway to treat fibro-inflammatory diseases including NASH, IPF, and organ-specific fibrosis. It operates a licensing model, monetizing its anti-IL-11 platform through partnerships with pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Antibody Therapeutics

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Antibody therapeutics
• Fibrotic disease treatment
• Interleukin-11 inhibitors
• Monoclonal antibody platform
• Biopharmaceutical licensing

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Licensing and Milestone Payments: Enleofen receives upfront and success-based development and commercialization milestones from pharmaceutical partners. Under the Boehringer Ingelheim agreement, Enleofen may receive payments in excess of one billion USD per product in upfront and success-based milestones. Revenue is generated through licensing deals where partners acquire exclusive rights to develop and commercialize therapeutic products.
2. Technology Licensing: The company licenses its intellectual property (patents and antibody products) to larger pharmaceutical companies. Enleofen was founded in 2017 with Series A funding and exclusively licensed a suite of patents and antibody products from the Academic Medical Centre.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Enleofen Bio Pte Ltd develops first-in-class monoclonal antibody therapeutics that target and inhibit the interleukin-11 (IL-11) cytokine to prevent, arrest, and reverse fibrosis and inflammation across multiple organs. Its lead candidate ENx108A is advancing through preclinical and clinical development for fibro-inflammatory diseases such as NASH, idiopathic pulmonary fibrosis, and chronic kidney disease, and the company licenses its anti-IL-11 platform to large pharmaceutical partners for downstream development and commercialization.

Product overview

Enleofen Bio Pte Ltd is a biotechnology company developing first-in-class antibody therapeutics targeting the IL-11 pathway for the treatment of fibro-inflammatory human diseases. The company's core product is ENx108A, a human monoclonal antibody and their first clinical development candidate. They have built an extensive anti-IL-11 antibody platform with multiple therapeutic antibodies targeting this pathway, which was exclusively licensed from the SingHealth Duke-NUS Academic Medical Centre. Their technology addresses diseases including IPF (idiopathic pulmonary fibrosis), NASH (non-alcoholic steatohepatitis), and chronic kidney disease by inhibiting IL-11 signaling to prevent and reverse fibrosis across multiple organ systems.

Differentiator

Problem solved

Functional benefit

Products and services

• ENx108A ENx108A is Enleofen's lead human monoclonal antibody therapeutic candidate and first clinical development lead. It is a powerful inhibitor of Interleukin-11 (IL-11) that combines exceptional efficacy and safety in preclinical studies with excellent manufacturing properties, and is designed to prevent, arrest, and reverse fibrosis and restore organ function in patients with fibro-inflammatory diseases such as NASH, IPF, and chronic kidney disease.
• Anti-IL-11 Antibody Platform The anti-IL-11 antibody platform is Enleofen's licensable portfolio of antibody-based IL-11 antagonists that prevent and reverse inflammation and fibrosis across liver, lung, kidney, retina, bowel, heart, and skin. It is licensed to pharmaceutical partners for clinical development, regulatory approval, and commercialization of first-in-class anti-fibrotic therapies, as demonstrated by the worldwide exclusive rights granted to Boehringer Ingelheim in 2020.

Quantifiable outcome

• Preclinical studies demonstrate ability to prevent and reverse fibrosis and restore organ function across liver, lung, kidney, heart, retina, bowel and skin
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core, supporting and founding.

• Boehringer IngelheimcoreStrategic or Co-development Partner · 9 January 2020Boehringer Ingelheim acquired worldwide exclusive rights to Enleofen's preclinical interleukin-11 (IL-11) platform to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The partnership combines Boehringer Ingelheim's expertise in fibrotic diseases with Enleofen's world-leading expertise in IL-11 biology. Boehringer Ingelheim will be solely responsible for clinical, regulatory, and commercial development. Enleofen may receive payments in excess of one billion USD per product in upfront and success-based milestones.
• Evercore Asia (Singapore) Pte. Ltd.supportingOthers · 9 January 2020Evercore Asia acted as Exclusive Financial Adviser to Enleofen on the landmark Boehringer Ingelheim transaction.
• AbzenasupportingTechnology or Integration · 14 November 2017Abzena supports Enleofen's fully human antibody development program using Composite CHO cell line technology. Abzena may support large scale manufacturing at their San Diego facility. They also provide protein engineering technologies to help translate preclinical findings to clinical applications.
• National Heart Centre Singapore (NHCS), SingHealth and Duke-NUS Medical SchoolfoundingStrategic or Co-development Partner · 4 April 2017Enleofen was founded as a spin-out from these academic institutions. The initial discovery science and drug target validation was carried out by founders Stuart Cook and Sebastian Schäfer at these institutions. A comprehensive suite of patents and antibody products was exclusively licensed to Enleofen at founding. The company continues to work jointly with scientists at the AMC to accelerate the platform into clinical development.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Emerging players

• Akeso Biopharma: China-based biotech with a pipeline of novel monoclonal antibodies including IL-targeting programs (e.g., ivonescimab, PD-1/VEGF bispecific). Comparable as an emerging antibody-platform biotech pursuing IL/cytokine biology in immuno-inflammatory indications.
• Morphic Holding: Clinical-stage biotech developing oral integrin inhibitors for fibro-inflammatory and immunologic diseases. Comparable as an emerging player targeting fibrosis and inflammation biology with novel biologics/small molecules.

Direct peers

• Galapagos NV: Belgium-based biotech with a fibrosis pipeline including ziritaxestat and other candidates for IPF and SSc-ILD. Comparable as a fibrosis-focused innovator pursuing novel mechanisms against fibro-inflammatory diseases.
• FibroGen: Biotech developing anti-fibrotic therapeutics (e.g., pamrevlumab targeting connective tissue growth factor in IPF and Duchenne muscular dystrophy). Closely comparable as a developer of monoclonal antibody / biologic therapies aimed at fibrotic disease mechanisms.
• Intercept Pharmaceuticals: Developed obeticholic acid for NASH and other fibrotic liver diseases. Comparable as a single-asset-focused biotech in the NASH/fibrosis space — also a cautionary comparator given the high-profile Phase 3 failure of obeticholic acid in NASH.
• Pliant Therapeutics: Clinical-stage biotech developing integrin-targeted therapeutics for idiopathic pulmonary fibrosis and other fibrotic diseases. Directly comparable as a fibrosis-focused biotech with similar disease targeting (IPF/NASH-adjacent) and a similar early-stage, single-platform business model.
• Madrigal Pharmaceuticals: Developer of resmetirom, a liver-directed thyroid hormone receptor agonist for NASH. Comparable as a small-cap biotech whose primary value driver is a single fibro-inflammatory / NASH asset advanced through clinical and commercial stages.

Broad incumbents

• Boehringer Ingelheim: The company that licensed Enleofen's IL-11 platform in 2020. Relevant as the large pharma incumbent that already markets nintedanib (Ofev) in IPF and is the lead developer of the IL-11 program — directly comparable in fibrotic disease R&D and commercial focus.
• Gilead Sciences: Large pharma that has invested heavily in NASH/fibrosis (selonsertib, FiraBev partnership). Comparable as a broad incumbent actively pursuing anti-fibrotic therapeutics in liver disease, illustrating the competitive field Enleofen's mechanism must differentiate against.
• Roche: Major pharma with established respiratory and fibrosis franchises (e.g., Esbriet/pifenidone in IPF) and a large antibody pipeline across fibro-inflammatory indications. Comparable as a broad incumbent operating in the same therapeutic space Enleofen targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enleofen Bio Pte Ltd